ClinicalTrials.gg
CompletedNCT00168350Updated Nov 4, 2010

Memantine in Patients With Chronic Glaucoma

A Phase 3 interventional study of memantine in Open-Angle Glaucoma, sponsored by Allergan. Completed. Open to participants aged 18 Years to 82 Years. Per ClinicalTrials.gov, last updated 2010-11-04.

Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,179
Allocation
Randomized
Ages
18 Years to 82 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies in Glaucoma, Open-Angle by AbbVie — 1 open to participants now, 3 under way, 1 of them phase 3. Glaucoma, Open-Angle · AbbVie.

Enrollment
Largest of 34
1,179 · median 164
Started
2000
the only one that year
Phase 3
12 of 58
1 open now
Registered
2nd of 58
by date

Among the 58 studies in Glaucoma, Open-Angle by AbbVie, this one has the largest enrollment of the 34 interventional ones that give a count, is the only one that started in 2000, is one of 12 in phase 3, and was the 2nd registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

1 of the 58 studies in Glaucoma, Open-Angle by AbbVie is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 82 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Glaucoma, Open-Angle by AbbVie, or all of them as a file.
02

Study summary

Randomized double-masked clinical trial of memantine in patients with glaucoma

03

Conditions studied

  • Open-Angle Glaucoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 82 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • glaucoma damage on examination of visual field and optic disc
  • good visual acuity (with glasses if needed)
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
1,179 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Progression of glaucoma

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2000, a primary completion of Sep 2006 and a completion of Sep 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 15, 2005
Start
Mar 2000
Primary completionActual
Sep 2006
CompletionActual
Sep 2006
Last update
Nov 4, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00168350
Lead sponsor
Allergan
First posted
Sep 15, 2005
Start date
Mar 2000
Primary completion
Sep 2006
Completion
Sep 2006
Last update
Nov 4, 2010

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Memantine

Start the discussion